Table 7. Open in new tab Direct-Acting...

Study Group	Participants Beginning DAA Treatment, No./Total (%)	P Value^a
Historical control	25/38 (66)	2/4 (50)	0/2 (0)	27/44 (61)	.01
Intervention (POCT)	37/39 (95)	6/10 (60)	4/6 (67)	47/55 (86)

Study Group	Participants Beginning DAA Treatment, No./Total (%)	P Value^a
Historical control	25/38 (66)	2/4 (50)	0/2 (0)	27/44 (61)	.01
Intervention (POCT)	37/39 (95)	6/10 (60)	4/6 (67)	47/55 (86)

Table 7.

Direct-Acting Antiviral Treatment for Hepatitis C Virus RNA–Positive Participants in Historical Control and Point-of-Care Testing Intervention

Study Group	Participants Beginning DAA Treatment, No./Total (%)				P Value^a
Study Group	Reception Prison	Inpatient AOD Unit	Inpatient MHS	Total	P Value^a
Historical control	25/38 (66)	2/4 (50)	0/2 (0)	27/44 (61)	.01
Intervention (POCT)	37/39 (95)	6/10 (60)	4/6 (67)	47/55 (86)

Study Group	Participants Beginning DAA Treatment, No./Total (%)				P Value^a
Study Group	Reception Prison	Inpatient AOD Unit	Inpatient MHS	Total	P Value^a
Historical control	25/38 (66)	2/4 (50)	0/2 (0)	27/44 (61)	.01
Intervention (POCT)	37/39 (95)	6/10 (60)	4/6 (67)	47/55 (86)

Abbreviations: AOD, alcohol and other drug; DAA, direct-acting antiviral; MHS, mental health service; POCT, point-of-care testing.

^aP value for Fisher exact test.